SECTION I: ESTIMATION OF COSTS
|
1 |
Taking into account the rest of the cost evaluation please provide an overall estimation of the total costs for full deployment/production of the R & D result. |
| … in terms of IPR protection | |
| The PCT patent application has been extended to the US (US13/058581) and Europe (EP2321346).
|
|
| …in terms of product development | |
|
|
|
| …in terms of mass production | |
|
|
|
| … in terms of marketing | |
|
2 |
Based on the above assessment as well as the marketing information please provide the correct estimation of thepriceforR&Dproduct in correlation with costs |
|||||
|
|
Year 1 |
Year 2 |
Year 3 |
Year 4 |
Year 5 |
|
|
Fixed costs |
|
|
|
|
|
|
|
Personnel |
|
|
|
|
|
|
|
Other running costs |
|
|
|
|
|
|
|
Marketing costs |
|
|
|
|
|
|
|
TOTAL EXPECTED COSTS |
|
|
|
|
|
|
|
Price per Unit |
|
|
|
|
|
|
|
Type of Unit |
|
|||||
|
Number of Units |
|
|
|
|
|
|
|
TOTAL Expected Revenues |
|
|
|
|
|
|
|
CASH FLOW REQUIRED (REVENUES-COSTS) |
|
|
|
|
|
|
|
TOTAL CAPITAL required for five years |
|
|||||
SECTION 2: QUALITATIVE FACTORS
|
3 |
Dimension of identified target groups |
| Big pharma. → Muscle disorder’s patients
|
|
|
4 |
Evaluation of financial Risks for R&D result |
| High.
|
|
SECTION 3: IDENTIFICATION OF FINANCING SOURCES
After evaluating all the above mentioned criteria, please tick the best financing source for the achievement of R&D result (i.e. own capitals, banking credits, venture capital, business angels, etc)
|
1. European Funding Define relevance of the product with the following potential funding sources and comment |
2. … 3. … 4. … |
|
2. National Funding |
|
1. … 2. … … |
|
3. Private funding |
|
1. They are looking for research collaborators for preclinical, clinical tests. 2. … 3. … … |
|
4. Other |
|
|
SECTION 3: FINAL EVALUATION
| It is requested a final evaluation considering the funding opportunities you believe most suitable for the exploitation of the R&D result, considering the possibility of the creation of a spin-off, further research, in particular, a cost/benefit analysis and a financial projection for the R&D result, type of collaboration identified (i.e. Licensing Agreement, Technical Cooperation, Joint Venture, Manufacturing Agreement, Commercial Agreement with Technical Assistance, Creation of a spin-off, Joint further development)… |
| The invention has needed further research and should be done the preclinical and clinical tests.
|
Decision of evaluation (Please keep only the appropriate)
- The R&D result needs moderate revisions
Tivadar Lippényi
